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Cognitive impairment in kidney transplantation (KTx) patients is associated with allograft 
survival and mortality. However, the prevalence of cognitive impairment after KTx is still 
understudied. Thus, we aimed to assess the prevalence of cognitive impairment in KTx 
patients and to identify sociodemographic, medical, donation-specific, and psychological 
variables associated with cognitive impairment. In this cross-sectional two-center study, 
583 KTx patients participated in a structured post-transplant care program. The DemTect 
was used to assess cognition, and cognitive impairment was defined as a score of < 13. 
Mean age was 52.11 years, 59% were male, 27.4% had ≥12 years of school attendance, 
and 85.9% had hypertension. The prevalence of cognitive impairment was 15.6%. 
Cognitive impairment was significantly associated with higher age, male sex, lower 
educational level, subjective perception of cognitive decline, higher rates of hypertension, 
lower kidney functioning, and obesity (BMI > 30 kg/m2). Using logistic regression 
analysis, all variables except age remained significant. Our results suggest that cognitive 
impairment affects a significant number of patients after KTx. Transplant centers may 
consider screening for cognitive impairment using objective tests, especially in patients 
with a high-risk profile. Furthermore, studies with longitudinal designs are required in order 
to assess moderators and mediators for cognitive trajectories.
Keywords: cognitive functioning, cognitive impairment, kidney transplantation, renal transplantation, DemTect
INTRODUCTION
Kidney transplantation (KTx) is the treatment of choice for patients with end-stage renal disease 
(ESRD) (1). Due to low numbers of deceased organ donors and an increase of ESRD patients, in 
general, the current waiting time of KTx candidates who undergo dialysis therapy is about 6 to 7 
years in Germany (2, 3). It is known that dialysis therapy is inferior to KTx regarding quality of life, 
morbidity, and mortality of ESRD patients.
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Previous studies have shown that cognitive impairment is a 
significant problem for patients on dialysis with prevalence rates 
ranging between 50% and 87% (4, 5). Additionally, cognitive 
impairment correlated with a higher risk of hospitalization and 
morbidity (6). Several risk factors for cognitive impairment in 
patients on dialysis such as reduced creatinine clearance, elevated 
homocysteine levels, arteriosclerosis, and rapid fluid and osmotic 
shifts have been identified so far (7, 8). In a recent meta-analysis, 
Joshee et al. (7) found moderate to substantial improvements 
in several cognitive domains based on neuropsychological tests 
in patients after KTx compared to their pre-donation scores. At 
the same time, patients after KTx still performed significantly 
lower in some domains compared to healthy controls (7). Thus, 
cognitive impairment may not be entirely reversible and cognitive 
functioning might deteriorate long term due to comorbid 
medical conditions and the neurotoxicity of immunosuppressive 
medication, especially calcineurin inhibitors (CNI) (7). However, 
no information on the prevalence of cognitive impairment after 
KTx is provided in this study. To our knowledge, the prevalence 
of cognitive impairment in KTx patients was explicitly evaluated 
in one study so far (9). Gupta et al. found a prevalence of cognitive 
impairment of 58.0% in 226 KTx patients by using the Montreal 
Cognitive Assessment (MoCA) (9, 10).
Additionally, two recent studies are evaluating cognitive 
impairment in KTx patients in two at least partially overlapping 
samples using the Modified Mini-Mental State Examination 
(3MS) (11, 12). The baseline prevalence rates of cognitive 
impairment were assessed immediately before transplantation 
and were 7.2% (11) and 10.0% (12), respectively. After 
transplantation, the authors described an improvement of 
cognitive functioning; however, prevalence rates of cognitive 
impairment after transplantation were not reported.
While neuropsychological tests provide a detailed evaluation 
of the participants’ cognitive performance, they are time-
consuming and cost-intensive and therefore not suitable for 
the use in daily clinical practice. Also, patients, especially those 
already experiencing cognitive impairment, might not agree 
to participate in detailed neuropsychological testing. Thus, we 
decided to use the DemTect which is suitable for the use in daily 
clinical practice and is a sensitive screening instrument to assess 
also mild cognitive impairment (MCI) (13). MCI is defined as 
the state between cognitive changes of aging and early dementia 
and is characterized by a decline of cognitive functioning 
compared to the past, but typically does not severely affect daily 
life (14, 15). The DemTect can detect MCI with a sensitivity 
of 80% and shows similar accuracy compared to the CERAD 
(Consortium to Establish a Registry for Alzheimer’s disease) test 
battery (16–18).
Additionally, the DemTect provides age-adapted scoring 
routines and is not education-dependent (19). Above that, there is 
an equivalent test for the DemTect-A available (DemTect-B). The 
versions can be mutually interchanged and, therefore, are helpful 
for follow-up investigations. As far as we know, the DemTect is 
the only instrument available in German which has a parallel 
version (20). These characteristics distinguish the DemTect from 
other screening instruments and make it an appropriate tool for 
our purpose.
Since cognitive impairment may interfere with the necessary 
self-care on the part of the transplant patients and has shown 
to be associated with inferior medical outcomes (12) screening 
for cognitive impairment after KTx is crucial. Reliable data on 
cognitive impairment in well-defined cohorts of KTx patients 
are scarce. Thus, the aim of this study was (1) to investigate 
the prevalence of cognitive impairment in KTx patients using 
the DemTect; (2) to identify sociodemographic, medical, 
donation-specific, and psychological variables associated with 
cognitive impairment; and (3) to compare our findings with 
previous research.
MeThODS
Participants
Participants were recruited within the structured post-transplant 
care program (KTx360°) conducted at the transplant centers of 
Hannover Medical School and Hannoversch Münden in Lower 
Saxony, Germany (21). Within this ongoing study, 1,200 KTx 
patients of at least 16 years of age were approached between May 
2017 and December 2018. Six hundred nineteen (51.6%) KTx 
patients took part in the study. The non-participants indicated 
that they were not interested in participating in a structured 
follow-up program. For the non-participants, only basic 
information was available. They were significantly older, had a 
longer time since KTx, had more often received an organ from a 
living kidney donor, had a higher rate of diabetes, and a lower rate 
of anemia compared to the participants. There was no significant 
difference regarding sex, renal functioning, and hypertension.
A medical doctor or psychologist performed a psychosocial 
risk assessment in all participating KTx patients. Parts of 
the assessment were a structured interview to detect mental 
comorbidity as well as an evaluation of adherence behavior. 
Above that, the assessment included the DemTect as a screening 
for cognitive impairment (13). Thirty-six of the 619 patients did 
not complete the DemTect due to the inability to speak fluent 
German, hearing or visual impairment or a known history of 
severe developmental delay. Five hundred eighty-three patients 
completed the DemTect and were included in the analyses.
The study was approved by the institutional ethics review 
board of Hannover Medical School (number 3464-2017), and all 
participants gave written informed consent.
assessment Instruments
Cognitive Functioning
Cognition was assessed with the DemTect, a brief and sensitive 
screening instrument for mild cognitive impairment (13). It can 
be performed in 8 to 10 min and consists of five tasks: a word list, a 
number transcoding task, a word fluency task, digit span reverse, 
and delayed recall of the word list. A summary of the different 
cognitive abilities evaluated in the five subtests can be found in 
Table 1. A maximum score of 18 can be reached. A score of 13 
to 18 corresponds to an age-adequate cognitive performance, 
a score of 9 to 12 corresponds to mild cognitive impairment, 
and a score of 8 or below raises the suspicion of the presence of 
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dementia. To control for age effects, there are different cut-offs 
for score transformation for participants younger than 60 years, 
and for those who are 60 years or older.
There are calculated bidirectional conversion tables available 
allowing the conversion and comparison of the German versions 
of the DemTect and the two other frequently used screening 
instruments MoCA and Mini-Mental State Examination 
(MMSE) (10, 22, 23).
Additionally, patients were asked if they have experienced 
subjective changes in their cognitive functioning since 
transplantation.
Symptoms of Depression and Anxiety
Anxiety and depression were measured with the German version 
of the Hospital Anxiety and Depression Scale (HADS) (24, 25). 
The self-report instrument is specifically designed to assess levels 
of anxiety and depression in physically ill patients. There are 
two subscales “depression” and “anxiety.” Each of the two scales 
consists of seven items. Each item is scored from 0 to 3, yielding a 
total score between 0 and 21. Higher scores indicate higher levels 
of depression or anxiety. Scores ≥ 11 are indicative of clinically 
relevant symptoms of anxiety or depression. Cronbach’s α in our 
sample was 0.872 for depression and 0.827 for anxiety.
Adherence
The Medication Adherence Rating Scale (MARS-D) is a five-
item self-report instrument assessing non-adherent behavior on 
a five-point Likert scale (26). In our study, the German version 
of the questionnaire was used (27). The total score ranges from 
5 to 25, with higher scores indicating higher adherence. Patients 
were considered to be non-adherent if they scored below 25 
(28, 29). For our study, patients were asked only to consider 
immunosuppressive medication in their ratings. The MARS-D 
was adapted accordingly with the approval of the original 
authors. Cronbach’s α in our sample was 0.669.
Medical Parameters
The medical parameters estimated glomerular filtration rate 
(eGFR) and creatinine at the time of administration of the 
DemTect and the presence of hypertension, renal anemia, 
and diabetes mellitus were taken from the medical records. 
Bodyweight and body height were measured using a standardized 
scale. Patients with a body mass index (BMI) of 30 kg/m2 or 
above were rated as obese.
Sociodemographic and Donation-Specific Variables
Sociodemographic and donation-specific variables including sex, 
age, partnership status, level of education, donation type, time 
since KTx, dialysis treatment, and dialysis duration were assessed 
using a self-report questionnaire, and missing information were 
obtained from the medical records.
Statistics
Questionnaire scores were calculated for the entire sample and 
separately for patients with and without cognitive impairment. 
For each variable descriptive statistics (percentage or mean and 
standard deviation) were calculated.
We used Shapiro-Wilk test and Kolmogorov-Smirnov test 
to evaluate data distribution. As our data were not normally 
distributed, Mann-Whitney U tests were used for comparison of 
continuous data between the sample with cognitive impairment 
and the sample without cognitive impairment. Chi-square tests 
were used for categorical data.
Binary logistic regression analysis with the DemTect 
(dichotomous) as the dependent variable and variables that were 
significant in the univariate tests as the independent variable 
were conducted. All patients with complete data sets (n = 552) 
were included in this analysis.
For all analyses, P < 0.05 was considered statistically 
significant. All statistical analyses were performed using IBM® 
Statistical Software Package of Social Science (SPSS®, Chicago, IL, 
USA) version 25.
ReSUlTS
Participant Characteristics
Participant characteristics are summarized in Table 2. Our sample 
comprised 239 women (41%) and 344 men (59%). The mean age at 
the time of assessment was 52.11 years (SD 14.25). 27.4% reported 
a school attendance of 12 years or more. 29.9% of the participants 
had received their kidney from a living kidney donor.
Regarding medical conditions, 85.9% were diagnosed with 
hypertension, 28.3% with renal anemia, and 17.4% with diabetes 
mellitus (type 1, type 2 or new-onset diabetes after transplantation 
(NODAT)). 20.6% had an eGFR below 30 ml/min/1.73 m2, 
corresponding to a severe reduction of the glomerular filtration 
rate (30). The BMI was available for 425 patients. Of those, 17.6% 
were obese.
Prevalence of Cognitive Impairment
In the screening for cognitive impairment using the DemTect, 
492 participants (84.4%) showed normal cognitive functioning 
(DemTect ≥ 13), 80 participants (13.7%) reached a DemTect 
score between 12 to 9 corresponding to mild cognitive 
impairment, and 11 participants (1.9%) had a DemTect score 
of 8 or below, indicative for severe cognitive impairment. Mild 
and severe impairments were taken together for further analyses 
(n = 91, 15.6%) (Figure 1). Figure 2 shows the mean score for 
each subtest as well as the mean sum score for patients with and 
without cognitive impairment. Using Mann-Whitney U tests we 
TaBle 1 | Cognitive domains evaluated with the subtests of the DemTect 
[adapted from Kessler et al. (20)].
Subtests Cognitive abilities
Wordlist Verbal memory
Number transcoding Lexical processing, syntactic processing, language 
processing (reading and writing), executive functioning
Semantic word 
fluency test
Attention, working memory, cognitive flexibility, 
problem-solving, imagery, semantic memory, 
language, speed of processing
Digit span reverse Working memory
Wordlist delayed recall Verbal long term memory
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found a statistically significant difference for each subtest and 
sum score.
To allow comparison with the study of Gupta et al. (9) the 
DemTect scores were converted into MoCA scores, leading to a 
mean value of 27.16 (SD 3.18) with 22.3% of the patients reaching 
a score below 26, indicating cognitive impairment.
When asked about subjective changes in cognitive functioning 
after KTx, answers were available from 574 patients. There were 
TaBle 2 | Comparison of demographic and clinical characteristics between KTx patients with and without cognitive impairment.
Patient characteristics all 
N = 583 (100%)a
DemTect <13 
N = 91 (15.6%)b
DemTect ≥ 13 
N = 492
Statistics 
χ2 test, Mann-Whitney U test
age (years), mean (SD) 52.11 (14.25) 55.32 (13.69) 51.46 (14.23) Z = −2.254, P = 0.024
Female gender 239 (41%) 25 (27.5%) 214 (43.5%) χ2 = 8.151 (df = 1), P = 0.004
≥12 years school attendance (n = 552) 151 (27.4%) 12 (14.5%) 139 (29.6%) χ2 = 8.177 (df = 1), P = 0.004
hypertension 501 (85.9%) 86 (94.5%) 415 (84.3%) χ2 = 6.553 (df = 1), P = 0.010
Renal anemia 165 (28.3%) 22 (13.3%) 143 (86.7%) χ2 = .905 (df = 1), P = 0.342
Diabetes mellitus (1,2, and NODaT) 101 (17.4%) 20 (24.2%) 81 (16.5%) χ2 = 1.608 (df = 1), P = 0.205
egFR (ml/min/1.73 m2), mean (SD) 45.75 (18.44) 40.46 (19.05) 46.73 (18.18) Z = −3.553, P = 0.001
Creatinine (mg/dl), mean (SD) 1.77 (0.69) 2.04 (0.79) 1.73 (0.67) Z = −3.884, P = 0.001
egFR < 30 ml/min/1.73 m2 120 (20.6%) 29 (31.9%) 91 (18.5%) χ2 = 8.401 (df = 1), P = 0.004
living donation 185 (29.9%) 20 (22.0%) 157 (31.9%) χ2 = 3.583 (df = 1), P = 0.058
Time since KT (months), mean (SD) 66.06 (68.58) 69.00 (76.4) 65.5 (67.11) Z = −0.161, P = 0.872
Time on dialysis (months), mean (SD) 60.25 (49.60) 62.48 (44.33) 59.84 (50.54 Z = −0.815, P = 0.415
MaRS-D score (adherence), mean (SD) 24.35 (1.33) 24.34 (0.96) 24.35 (1.38) Z = −0.665, P = 0.506
haDS anxiety score, mean (SD) 5.13 (3.92) 5.18 (4.29) 5.13 (3.86) Z = −0.255, P = 0.799
haDS Depression score, mean (SD) 4.35 (4.00) 4.85 (4.69) 4.25 (3.87) Z = −0.675, P = 0.500
Subjective change of cognitive functioning 
(n = 574)
 Worse
 Improved
 No change
133 (23.2%)
61 (10.6%)
380 (66.2%)
26 (28.9%)
3 (3.3%)
61 (67.8%)
107 (22.1%)
58 (12.0%)
319 (65.9%)
χ2 = 6.889 (df = 2), P = 0.032
BMI ≥30 kg/m2 (n = 425) 75 (17.6%) 19 (29.7%) 56 (15.5%) χ2 = 7.516 (df = 1), P = 0.006
aPercent of all participants, bpercent of the demographic variable or clinical characteristic.
P < 0.05 was considered statistically significant, DemTect <13 = patients with cognitive impairment, DemTect ≥13 = patients without cognitive impairment; statistically significant 
results (P < 0.05) are shown in boldface. The significance of bolded texts is p < 0.05 as suggested.
FIgURe 1 | Distribution of DemTect sum scores.
October 2019 | Volume 10 | Article 791Frontiers in Psychiatry | www.frontiersin.org
Cognitive Impairment After Kidney TransplantationNöhre et al.
5
23.2% reported worsened cognitive functioning, while 10.6% 
reported improved cognitive functioning, and 66.2% did not 
perceive any change in cognitive functioning.
Comparison of Demographic and Clinical 
Characteristics Between KTx Patients 
With and Without Cognitive Impairment
KTx patients with cognitive impairment (age-adjusted score < 13) 
differed significantly from those without cognitive impairment 
(age-adjusted score ≥13) in all five subtests (data not shown). 
KTx patients with cognitive impairment were significantly older, 
the percentage of male patients was significantly higher, and the 
rate of patients with ≥12 years of education was significantly lower 
compared to those without cognitive impairment (Table 2).
In the group with cognitive impairment, significantly more 
patients reported subjective worsening of cognitive functioning 
compared to the other group (Table 2).
The percentage of patients with hypertension was significantly 
higher in the group with cognitive impairment. No differences 
between the groups were found regarding the rate of renal anemia 
and diabetes mellitus. However, KTx patients with cognitive 
impairment had significantly lower eGFR, and higher creatinine 
values, and the percentage of patients with an eGFR below 30 
ml/min/1.73 m2 was significantly higher in the group with 
cognitive impairment compared to the group without cognitive 
impairment (Table 2).
There were no differences regarding donation type, time since 
KTx, and time on dialysis between patients with and without 
cognitive impairment. Additionally, the groups did not differ 
regarding adherence rates measured with the MARS-D and 
symptoms of depression and anxiety evaluated with the HADS 
(Table 2).
In the subgroup of 425 patients with measured weight 
and height data, significantly more patients with cognitive 
impairment were obese at the time of the assessment compared 
to patients without cognitive impairment (Table 2).
Binary logistic regression analysis with the DemTect 
(dichotomous) as the dependent variable and sex, age, educational 
level, the presence of hypertension, and eGFR as independent 
variables was performed. The results are reported in Table 3. All 
independent variables except age remained significant.
DISCUSSION
The primary aim of this study was to assess the prevalence 
and correlates of cognitive impairment in KTx patients using 
the DemTect. This is of clinical interest, since recent studies 
suggest that cognitive impairment might be associated with 
an increased risk of all-cause graft loss in KTx patients (12). 
In our study, 15.6% of the participants had DemTect scores 
below 13, indicating cognitive impairment. These numbers 
are significantly lower than the results of Gupta et al. (9), 
who found cognitive impairment in 58% of the KTx patients 
in their cohort, and more in line with the results of Chu et 
al. and Thomas et al. (11, 12) who reported prevalence 
rates of 7.2% and 10%, respectively, in patients immediately 
FIgURe 2 | Mean subtest scores and mean sum score for patients with and without cognitive impairment.
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before KTx using a modified version of the MMSE (3MS). 
Since the studies used different tests to evaluate cognitive 
impairment, the results are not directly comparable. Thus, 
we transformed the DemTect scores into MoCA scores using 
suggested conversion tables (23). However, the prevalence 
rate of cognitive impairment stayed significant lower in our 
sample (22.3%) compared to the rate reported by Gupta et al. 
(9). Unfortunately, no transformation scores into the 3MS are 
available. While the participants in the Gupta et al. (9) study 
had higher educational levels (57.5% ≥ 12 years vs. 27.4% ≥ 12 
years) and better renal functioning (eGFR 52 ml/min/1.73 m2 
vs. 45.75 ml/min/1.73 m2), they also had a markedly higher 
obesity rate (50.9% BMI > 30 kg/m2 vs. 17.6% BMI > 30 kg/m2) 
compared to the sample in our study which might at least in 
part account for this difference.
The DemTect results were significantly associated with 
the subjective experience of change of cognitive functioning 
since transplantation. However, most participants reported no 
subjective change in cognitive functioning (66.2%), and more 
participants reported a decline (23.2%) than an improvement 
(10.6%). One has to keep in mind that subjective perception 
might differ significantly from objective results, and the 
DemTect most likely is not sensitive enough to detect minor 
changes. However, the subjective impression might be an 
important indicator of changes in cognitive functioning. 
As a consequence for clinical practice, we would suggest 
screening the patients reporting a subjective decline in 
cognitive functioning.
Lower DemTect scores were associated with older age, male 
gender, and a lower educational level which is in line with 
previous studies (9). It is well known that the prevalence of 
cognitive impairment increases with age (31), but this occurs 
earlier in life in KTx patients than in the general population 
(7). However, when using logistic regression analysis with the 
DemTect (dichotomous) as the dependent variable, age did 
not remain significantly associated. The result supports the 
allegation that when using the age-adapted DemTect scores for 
patients older and younger than 60 years, no further adaptions 
are required to control for age (13).
Concerning gender, female participants showed significantly 
less often cognitive impairment compared to male participants. 
This difference remained significant after controlling for other 
significantly associated variables such as eGFR, hypertension, 
and educational level and cannot be explained by differences 
in these variables between genders. It is well known that 
probably due to hormonal effects, atherosclerosis aggravates 
slower in women than in men resulting for instance, in a 5-year 
gap between men and women suffering from stroke (32). Of 
note, CKD is associated with abnormalities in sex hormones, 
and KTx has been shown to normalize serum sex hormone 
concentrations (33, 34). Thus, female sex hormones might 
exert a protective effect against CNI induced progression 
of atherosclerosis.
There were significantly more patients with 12 or more years of 
education in the group without cognitive impairment compared 
to the other group. A recent review of Lenehan et al. (35) suggests 
that people with a higher educational level can perform longer at 
a higher level compared to less educated individuals. Therefore, 
it takes more time until cognitive impairment becomes apparent. 
However, it remains unclear if there is a difference regarding the 
cognitive decline in higher and lower educated individuals (35).
The rate of patients diagnosed with hypertension was 
significantly higher in the group with cognitive impairment. 
This finding is in accordance with previous results showing that 
high blood pressure, especially at middle age, is associated with a 
higher risk for cognitive impairment (36). Possible mechanisms 
might be an increased occurrence of atherosclerosis and other 
cardiovascular comorbidities (36). Due to the design of our 
study, we have no information on the way hypertension has been 
treated in the past in our participants. Nevertheless, our results 
support the association between hypertension and cognitive 
impairment. From a clinical perspective efficient treatment of 
hypertension is strongly recommended.
Other medical conditions such as diabetes mellitus and 
anemia can be associated with cognitive impairment as well (37–
39); however, in our study, no differences between the groups 
were found regarding the rate of renal anemia and diabetes 
mellitus. One explanation might be that we took the diagnoses 
from the patient charts without any further information on the 
current status of the disease. Especially anemia can be treated 
successfully, leading to a complete remission of associated 
symptoms. Therefore, the occurrence of the diagnosis might not 
be automatically associated with the presence of symptoms and 
possible long-term effects.
In patients with CKD—and not exclusively ESRD—it is well 
known that cognitive impairment increases in prevalence and 
severity with declining kidney functioning (7, 40, 41). In our 
study, participants with cognitive impairment had a significantly 
lower eGFR compared to those without cognitive impairment. 
In contrast to the results of Gupta et al. (9), our findings support 
TaBle 3 | Binary logistic regression analysis with DemTect (dichotomous) as the dependent variable and variables that were significant in the univariate tests as the 
independent variable (n = 552).
Variable Regression 
coefficient B
Standard 
error
Wald df Sig. exp(B) OR 95% CI, 
lower
95% CI, 
upper
Presence of hypertension 0.972 0.488 3.962 1 0.047 2.643 1.015 6.881
Male gender 0.712 0.267 7.118 1 0.008 2.037 1.208 3.436
<12 years of school attendance 0.892 0.336 7.051 1 0.008 2.441 1.263 4.716
Age (years) 0.009 0.009 0.937 1 0.333 1.009 0.991 1.028
eGFR (ml/min/1.73 m2) −0.020 0.008 7.014 1 0.008 0.980 0.965 0.995
Constant −3.376 0.841 16.114 1 0.000 0.034
Goodness of fit for the final model was based on Hosmer-Lemeshow test which was not significant (χ2 = 3.273, df = 8, P = 0.916).
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the hypothesis that mechanisms responsible for cognitive 
impairment in patients with CKD might also play an essential 
role in cognitive functioning in KTx patients with reduced eGFR 
as suggested by Van Sandwijk et al. (8).
Donation-specific variables seem to play a marginal role 
in cognitive functioning after KTx. While there is evidence 
that shorter time on dialysis and living kidney donation are 
associated with a better outcome after transplantation (42), this 
was not—and in the case of living kidney donation marginally—
associated with cognitive functioning in our sample. Also, 
we found no association between time passed since KTx and 
cognitive functioning. In conjunction with the results described 
above, these findings suggest that kidney function might have 
a stronger association with cognitive functioning compared to 
donation-specific variables.
It is well known that non-adherence to immunosuppressants 
is a risk factor for transplant rejection (43). One reason for 
non-adherent behavior might be cognitive impairment (44, 
45). However, we found no difference regarding self-reported 
adherence between patients with and without cognitive 
impairment. On the one hand, impaired cognitive functioning 
can be compensated by social support and practical strategies 
to improve adherence (45). On the other hand, self-report 
instruments might not be the perfect tool to assess adherence 
in patients with cognitive impairment because they might not 
remember correctly if they have taken their medication.
Anxiety and depression are common mental disorders in 
the general population and have an even higher prevalence in 
patients after organ transplantation (46). Depression is known 
to affect cognitive functioning (47). In our study; however, 
there was no difference regarding symptoms of depression 
and anxiety between the patients with and without cognitive 
impairment. In both groups the mean scores for the subscales 
“depression” and “anxiety” were clearly below the suggested 
cut-off of 11 (Table 2), indicating low symptom severity in 
both groups which might explain the lack of association with 
cognitive functioning.
In a subgroup of our sample, measured weight and height were 
available. We found a significantly higher rate of obesity (BMI > 
30 kg/m2) in the group of patients with cognitive impairment 
in comparison to the group without cognitive impairment. The 
rising overall prevalence of obesity in the general population 
is mirrored in the transplant population and prevalence rates 
of 16% to 20% can be found (48, 49). This finding is in good 
agreement with other results: In a recent review by Monda et 
al. (50), a significant association was detected between obesity 
and cognitive impairment. Additionally, obesity in patients after 
KTx is associated with a higher risk for adverse events including 
higher rates of diabetes mellitus, dyslipidemia, and hypertension 
as well as a higher risk of mortality and graft failure (51). With 
declining graft function and hypertension being identified as 
risk factors for cognitive impairment in KTx patients, it becomes 
evident that obesity influences cognitive functioning at least 
indirectly. However, the evidence is still lacking if obesity is an 
independent risk factor for cognitive impairment (50).
Some limitations are worth noting. Due to the cross-sectional 
design of our study, we can only describe correlates and can make 
no assumptions regarding cause and effect. Another limitation 
is the use of a single screening measure of cognitive function 
(the DemTect) that is unable to detect domain-specific effects 
compared to comprehensive neuropsychological test batteries. 
As there are no baseline data available before transplantation, 
we do not know if there are objective changes in cognitive 
functioning after transplantation. More detailed information 
on comorbidities and complications post-treatment, such as 
infections or acute rejection episodes that may also influence 
cognitive function were not captured in our study. Finally, we 
have to take the possibility of a selection bias into account as 
we cannot be sure that the 619 participating KTx patients are 
representative of the whole population of KTx patients.
In conclusion, the findings of our study suggest that 
cognitive impairment affects a significant number of patients 
after KTx. This is of relevance since cognitive dysfunction has 
shown to be associated with an elevated risk of graft loss and 
also often precedes dementia. Furthermore, we were able to 
identify variables that are associated with cognitive impairment 
such as male gender, lower educational level, the presence of 
hypertension, and lower kidney functioning. Since the clinical 
perception of cognitive impairment by nurses and physicians 
has shown to be inaccurate in detecting cognitive impairment in 
KTx patients (52), transplant centers may consider screening for 
cognitive impairment using objective tests especially in patients 
with a high-risk profile. Centers should address cognitive decline 
by implementing management strategies such as cognitive or 
physical exercise training. However, the evidence for available 
strategies is still limited, and further research is required in 
this field. We will continue to evaluate cognitive functioning 
longitudinally in the participants of our study since cognitive 
trajectories over a longer period, putative moderators, and 
mediators of change are still understudied.
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